Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A medicine composition for treating renal interstitial fibrosis

A kind of technology of renal interstitial fibrosis and composition, which can be applied in the field of medicine and can solve the problems of rosiglitazone and puerarin in renal interstitial fibrosis, etc.

Inactive Publication Date: 2018-12-07
ZHEJIANG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the combination of rosiglitazone and puerarin in the treatment of renal interstitial fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A medicine composition for treating renal interstitial fibrosis
  • A medicine composition for treating renal interstitial fibrosis
  • A medicine composition for treating renal interstitial fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] 1. Cell culture

[0029] HK-2 cells (human renal tubular epithelial cells) were cultured in DMEM / F12 medium containing 10% FBS (fetal bovine serum) and 1% double antibody, and cultured in a cell culture box until the cells grew to 70% When -80% confluent, digest with 0.05% trypsin-EDTA solution. For the experiment, the above-mentioned HK-2 cells were placed in low-sugar DMEM medium for 2 passages, seeded in a 96-well plate at 5000 cells / well, and grown adherently in a cell culture incubator for 24 hours, then replaced with serum-free Wushuang Antibiotics were cultured overnight in low-glucose DMEM medium. Afterwards, the old culture medium was discarded and processed in groups.

[0030] 2. Grouping

[0031] A control group, a model group, a puerarin treatment group, a rosiglitazone treatment group and a pharmaceutical composition group were set up. In the control group, only 100 μL of low-sugar DMEM culture solution was added, which was regarded as normal culture. I...

Embodiment 2

[0040] 1. Cell culture

[0041] HK-2 cells were cultured in DMEM / F12 medium containing 10% FBS and 1% double antibody, and cultured in a cell incubator. When the cells grew to 70%-80% confluence, they were treated with 0.05% trypsin EDTA solution for digestion. For the experiment, the above-mentioned HK-2 cells were subcultured twice in low-sugar DMEM medium, and then seeded 400,000 cells / well in a 6-well plate. Serum-free double-antibody-free low-glucose DMEM medium was cultured overnight. Afterwards, the old culture medium was discarded and processed in groups.

[0042] 2. Grouping

[0043] A control group, a model group, a puerarin treatment group, a rosiglitazone treatment group and a composition group were set up. Only 100 μL of low-sugar DMEM culture solution was added to the blank group, and 100 μL of 60 mM high-glucose culture solution was added to the other groups, and the drug concentrations contained in the culture solution were shown in Table 2.

[0044] Conta...

Embodiment 3

[0054] 1. Cell culture method

[0055] HK-2 cells were cultured in DMEM / F12 medium containing 10% FBS and 1% double antibody, and cultured in a cell incubator. When the cells grew to 70%-80% confluence, they were treated with 0.05% trypsin EDTA solution for digestion. For the experiment, the above-mentioned HK-2 cells were subcultured twice in low-sugar DMEM medium, and then seeded 400,000 cells / well in a 6-well plate. Serum-free double-antibody-free low-glucose DMEM medium was cultured overnight. Afterwards, the old culture medium was discarded and processed in groups.

[0056] 2. Grouping method

[0057] A control group, a model group, a puerarin treatment group, a rosiglitazone treatment group and a composition group were set up. Only 100 μL of low-sugar DMEM culture solution was added to the blank group, and 100 μL of 60 mM high-sugar culture solution was added to the other groups. The drug concentrations contained in the culture solution are shown in Table 3.

[0058...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A medicine composition for treating renal interstitial fibrosis is disclosed. Effective components of the composition are rosiglitazone or a pharmaceutically acceptable salt thereof and puerarin. Thepharmaceutically acceptable salt of the rosiglitazone is one of rosiglitazone hydrochloride or rosiglitazone maleate or a combination thereof. The composition has significant antifibrosis activity, anti-inflammatory activity and antioxidation stress activity which are superior to those of a single medicine, and can significantly improve renal interstitial fibrosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for treating renal interstitial fibrosis. Background technique [0002] End-stage renal disease is the final stage of various chronic kidney diseases, mainly manifested as glomerulosclerosis and renal interstitial fibrosis. At this stage, the patient's renal function is irreversibly damaged, or even renal failure; end-stage renal disease is a major disease that threatens global human health. Fibroblasts are the main effector cells in the process of renal interstitial fibrosis. In normal kidney tissue, fibroblasts account for about 6% of the total number of cells, while this value reaches 60% in fibrotic kidney tissue. The increased number of fibroblasts arises on the one hand from their own proliferation and on the other hand from the transformation of tubular epithelial cells into fibroblasts or myofibroblasts (termed epithelial-mesenc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4439A61K31/352A61P13/12A61P29/00A61P39/06
CPCA61K31/352A61K31/4439A61P13/12A61P29/00A61P39/06A61K2300/00
Inventor 程翼宇王毅杨继鸿
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com